Cencora, Inc. (NYSE:COR) CEO Steven H. Collis has recently engaged in significant trading of the company's stock, according to a new SEC filing. On August 20, Collis sold 10,754 shares of Cencora common stock, with the total value of the sale amounting to approximately $2.57 million, at an average price of $239.13 per share.
The transactions were conducted under a pre-arranged 10b5-1 trading plan, which allows company insiders to set up a trading schedule in advance to avoid accusations of trading on inside information. This plan was established on December 18, 2023, and disclosed in a Company's 8-K filing with the SEC shortly thereafter.
In addition to the sale, the filing also reported that Collis acquired the same number of shares through the exercise of options at a price of $89.58 per share, totaling around $963,343. These options were exercisable in four equal installments over the past four years, with the final installment becoming available in 2022.
Following these transactions, Collis's direct ownership in the company stands at 285,088 shares of common stock. This reflects his active role in the company's equity transactions and his ongoing investment in Cencora's future.
Cencora, Inc., formerly known as AmerisourceBergen (NYSE:COR) Corp, is a leader in the wholesale distribution of pharmaceuticals and healthcare products. The company has a strong presence in the industry and continues to focus on growth and innovation in its sector.
Investors and market watchers often pay close attention to insider transactions as they may provide insights into the company's performance and the confidence that executives have in the company's prospects. The recent trades by Cencora's CEO will likely be of interest to the investment community as they evaluate the company's stock performance and future potential.
In other recent news, Cencora, a global pharmaceutical solutions company, has reported notable advancements. The company's third quarter financial results for fiscal 2024 show a robust growth, with quarterly revenue exceeding $74 billion, an 11% year-over-year increase. Additionally, the adjusted diluted earnings per share (EPS) rose by 14%, reaching $3.34.
In light of these results, Cencora has raised its full-year outlook, attributing this positive adjustment to its successful pharmaceutical-centric strategy and commercial strength. The company's OneOncology business received special mention for its performance and growth potential, which is expected to contribute positively to the EPS growth rate.
On the corporate front, Cencora announced the appointment of Frank Clyburn, former CEO and board member of International Flavors and Fragrances Inc., to its Board of Directors. Clyburn's extensive experience in the pharmaceutical industry is anticipated to be a valuable resource for Cencora's long-term growth strategies. Lastly, Cencora reported a cash balance of $3.3 billion, following opportunistic share repurchases. These represent the recent developments for Cencora.
InvestingPro Insights
As Cencora, Inc. (NYSE:COR) navigates the competitive landscape of pharmaceuticals and healthcare product distribution, its financial health and market performance remain critical to investors. With a robust market capitalization of $46.84 billion and a price-to-earnings (P/E) ratio of 25.73, Cencora stands out as a significant entity in its sector. Notably, the company's P/E ratio adjustment for the last twelve months as of Q3 2024 signals a slightly more attractive valuation at 22.1, reflecting investor confidence in its earnings potential.
InvestingPro Tips highlight that Cencora has been a consistent performer with a history of raising its dividend for 19 consecutive years, indicating a stable and investor-friendly approach to capital allocation. Moreover, the company is recognized as a prominent player in the Healthcare Providers & Services industry, reinforcing its market position.
InvestingPro Data further reveals a revenue growth of 11.56% over the last twelve months as of Q3 2024, showcasing Cencora's ability to expand its top-line figures in a challenging market. However, the company's gross profit margin stands at 3.37%, which might raise concerns about its pricing power and cost management strategies. Despite these challenges, the company's share price has been performing well, trading near its 52-week high and reflecting a price 96.59% of that peak.
For those interested in a deeper dive into Cencora's financials and market performance, InvestingPro offers additional insights. Currently, there are 18 more InvestingPro Tips available for Cencora, which can be accessed by visiting https://www.investing.com/pro/COR. These tips provide valuable information for investors looking to make informed decisions about their investments in Cencora.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.